All In Biotech

Drug Trial Radar · NCT06220864

SNV1521 in Participants With Advanced Solid Tumors

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Feb 23, 2024

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
ParVation Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.

Conditions

  • Advanced Solid Tumor

Interventions

  • SNV1521Drug

    SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.

  • DB-1310Drug

    DB-1310 is given as an infusion. Dose and frequency are dependent upon treatment arm.

  • AbirateroneDrug

    Abiraterone is taken orally. Dose and frequency are per approved prescribing instructions.

  • DarolutamideDrug

    Darolutamide is taken orally. Dose and frequency are per approved prescribing instructions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of SNV1521Time frame: From first dose through last dose (up to 13 months)
  2. Tolerability of SNV1521Time frame: DLTs: From first dose through completion of first cycle (28 days)

Locations

25 sites in 7 countries. Site status is shown where the registry gives one.

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • START Center for Cancer Care

    West Valley City, Utah · Recruiting

  • Scientia Clinical Research

    Randwick, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Linear Clinical Research

    Crawley, Western Australia, Australia · Recruiting

  • The Institut Jules Bordet

    Brussels, Belgium · Recruiting

  • University Center for Clinical Research Antwerp (UNICCRA)

    Edegem, Belgium · Recruiting

  • AZ Maria Middelares

    Ghent, Belgium · Recruiting

  • AZ Groeninge

    Kortrijk, Belgium · Recruiting

  • Arthur J.E. Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada · Recruiting

  • Princess Margaret Hospital

    Toronto, Ontario, Canada · Recruiting

  • Institut Bergonie

    Bordeaux, France · Recruiting

  • UNICANCER - Centre Leon-Berard (CLB)

    Lyon, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Istituto Clinico Humanitas

    Milan, Italy · Recruiting

  • Istituto Europeo di Oncologia (IEO) (European Institute of Oncology)

    Milan, Italy · Recruiting

  • NEXT Oncology - Barcelona

    Barcelona, Spain · Recruiting

  • Vall d'Hebron University Hospital

    Barcelona, Spain · Recruiting

  • The START Center for Cancer Care - Madrid - CIOCC - Hospital Universitario Madrid Sanchinarro

    Madrid, Spain · Recruiting

  • NEXT Oncology - Hospital Quironsalud Madrid

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.